Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
Drug discovery
-
Investors wary as Elanco pins hopes on new products
Shares in the animal health care company have lost more than two-thirds of their value in the past 18 months, but Elanco says a bevy of new products in its pipeline will prove an era of strong growth is yet to come.
Read More -
Eli Lilly’s Alzheimer’s drug hits roadblock
The FDA has agreed to speed up review of donanemab, but the Centers for Medicare and Medicaid Services is moving to limit reimbursement for drugs in this class to only patients in clinical trials.
Read More -
Eli Lilly inks R&D pact with Canadian pharma company
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.
Read More -
Lilly signs deal with California biotech to develop treatments for Lou Gehrig’s disease
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.
Read More
Articles
Omicron may sideline Lilly, Regeneron antibody drugs against COVID-19
The companies say they can quickly develop new omicron-targeting antibodies, but those aren’t expected to launch for at least several months.
Purdue-based startup gets FDA approval for cancer-targeting drug
It’s a big moment for On Target Laboratories, an 11-year-old biotech based in West Lafayette. The FDA approval marks the company’s first novel compound to get across the finish line. The drug is marketed under the brand name Cytalux.
Lilly’s COVID therapy hits wall as virus wanes
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
FDA approves much-debated Alzheimer’s drug panned by experts
The decision, which could affect millions of older Americans and their families, also has far-reaching implications for the standards used to evaluate experimental therapies, including those that show only incremental benefits.
Lilly’s Alzheimer’s drug shows modest benefit in mid-stage trial
Eli Lilly and Co. on Saturday morning presented highly anticipated details from a mid-stage study showing that its experimental drug slowed Alzheimer’s disease progression over about 18 months.
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
Fishers firm to help push injectables to market faster
A startup that’s planning to launch a $60 million drug-manufacturing plant sees big growth in contract manufacturing.
Regulators, experts take up thorny COVID-19 vaccine study issues
On Thursday, a federal advisory committee will debate whether the guidelines the FDA has set for vaccine developers are rigorous enough. Interest is so high, the FDA is airing the meeting on YouTube.
Antibody drugs are no cure but seem promising for COVID-19
Experimental antibody drugs like the one President Trump was given and the one Eli Lilly is developing are among the most promising therapies being tested for treating and preventing coronavirus infections. Here’s how they work.
Scioto Biosciences lands $26.5 million from Korean biotech
The Indianapolis-based startup is developing drugs targeting brain and bowel disorders.
After years of turmoil, biotech testing firm aims to grow again
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
Richard Wood, CEO of Lilly during transformational era, dies at 93
Eli Lilly and Co.’s breakthroughs during Wood’s 18-year tenure included biosynthetic insulin and the category-smashing antidepressant Prozac.
Court rejects Lilly’s challenge of competitor’s patents on migraine drug
Eli Lilly and Co.’s treatment Emgality and Teva Pharmaceutical’s drug Ajovy were approved within months of each other in 2018.
Indy startup Outpost Medicine draws in big money to develop drug therapies
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
New Lilly R&D chief planning blitz of drug launches
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
Lilly signs licensing deal with biotech startup for diabetes drug
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.